A journey through infectious risk associated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16174
Abstract: Ruxolitinib has proved to be effective for the treatment of patients with myelofibrosis (either primary or secondary) and polycythaemia vera, and its approval led to a significant change in the current treatment algorithm. Despite its… read more here.
Keywords: risk associated; risk; infectious risk; journey infectious ... See more keywords